Poseida therapeutics to present clinical and preclinical data on investigational allogeneic car-t cell therapies at sitc 2024 and ash 2024

New preclinical data on allogeneic car+tcr-t cells rich in stem cell memory t cells (tscm) and enhanced potency to better target solid tumors will be presented at sitc additional profiling of patient responses in p-bcma-allo1 phase 1 arm c and preclinical p-cd19cd20-allo1 to be presented at ash san diego , nov. 5, 2024 /prnewswire/ -- poseida therapeutics, inc. (nasdaq: pstx), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic car+tcr-t cells rich in stem cell memory t cells (tscm), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the society for immunotherapy of cancer (sitc) 39th annual meeting in houston, november 6-10. additionally, the company announced presentations at the 66th american society of hematology (ash) annual meeting & exposition, which will be held december 7-10 in san diego.
CAR Ratings Summary
CAR Quant Ranking